Red Blood Cells Contribute Alpha-Synuclein to Parkinson's Brain Pathology

Parkinson's Disease: Unraveling Systemic Contributions to Brain Pathology

Parkinson's disease is clinically defined by the progressive loss of dopaminergic neurons and the accumulation of misfolded alpha-synuclein aggregates in the brain [1, 2]. While this central nervous system pathology has long been the focus, a growing body of evidence suggests that systemic factors and peripheral processes significantly influence disease onset and progression [3, 4, 5]. Key among these are neuroinflammation driven by activated microglia [6, 7] and the integrity of the blood-brain barrier, which regulates molecular traffic between the periphery and the brain [8, 9]. A recent study now provides a direct link between these elements, investigating how a specific peripheral source of alpha-synuclein may contribute to the central neurodegenerative cascade.

Erythrocytes: A Peripheral Reservoir of Alpha-Synuclein

While the accumulation of alpha-synuclein in the central nervous system is a known driver of neurodegeneration in Parkinson's disease, the contribution of alpha-synuclein from outside the brain has been a significant knowledge gap. A new investigation using human tissues and mouse models addresses this by identifying erythrocytes as an important reservoir of alpha-synuclein. This finding repositions red blood cells as a potentially significant systemic player in the disease process. The study further demonstrates that bone marrow-derived erythrocytic alpha-synuclein likely contributes to brain pathology and Parkinson’s disease-related neurodegeneration, establishing a potential pathway from the hematopoietic system to the brain.

Peripheral Alpha-Synuclein Reaches the Brain and Activates Microglia

To trace the path of this peripheral protein, the researchers used bone marrow transplantation in mouse models. The experiments confirmed a widespread distribution of bone marrow-derived alpha-synuclein in peripheral organs. Although this alpha-synuclein was also detectable in the brain, its levels were substantially lower, suggesting that its entry into the central nervous system is a tightly regulated process. Once inside the brain, the study found that bone marrow-derived alpha-synuclein preferentially accumulated in resident microglia, the brain's innate immune cells. This specific uptake was confirmed using two complementary techniques: immunophenotyping, which identifies cells by their protein markers, and single-nucleus RNA sequencing, a high-resolution method for analyzing gene expression in individual cells. Critically for clinical pathology, this accumulation was associated with microglial activation, a state linked to the neuroinflammation that perpetuates neuronal damage in Parkinson's disease. The researchers also showed that erythrocyte-derived extracellular vesicles carrying alpha-synuclein can be readily taken up by microglia in vivo, offering a specific mechanism for this peripheral-to-central transfer.

Functional Impact: Dopaminergic Dysfunction and Neurodegeneration

The presence of peripheral alpha-synuclein in the brain is not merely an incidental finding; it has direct functional consequences. The study demonstrated that in mouse models, elevated levels of bone marrow-derived alpha-synuclein in the brain resulted in dopaminergic dysfunction under baseline conditions. This is a clinically significant outcome, as the impairment of dopamine-producing neurons is the direct cause of the motor symptoms seen in patients. Furthermore, this influx of peripheral alpha-synuclein also produced a mild neurodegenerative phenotype under baseline conditions, suggesting that even without other insults, a systemic supply of this protein can initiate or sustain damage. These findings imply that a chronic, low-level influx of alpha-synuclein from erythrocytes may be a contributing factor to the insidious onset and progression of central nervous system pathology in Parkinson's disease.

Blood-Brain Barrier Integrity as a Critical Regulator

The investigation identified a crucial gatekeeper in this process: blood-brain barrier integrity critically regulated peripheral alpha-synuclein entry into the central nervous system. To test this, the researchers used several methods to transiently increase barrier permeability. They found that disruption of the blood-brain barrier via endotoxin administration, mannitol treatment, or focused ultrasound markedly increased the entry of peripheral alpha-synuclein into the brain. This increased entry had severe consequences, as it aggravated both neurodegeneration and behavioral deficits in the animal models. These results collectively identify bone marrow-derived erythrocytic alpha-synuclein as a systemic contributor to the pathogenesis of Parkinson’s disease. More importantly for future therapeutic strategies, the findings highlight that blood-brain barrier integrity is a key permissive regulator of peripheral-to-central alpha-synuclein transmission. This suggests that conditions which compromise the barrier, such as systemic inflammation or trauma, could accelerate disease progression, and conversely, that strategies to maintain barrier integrity could be protective.

References

1. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease. Science. 1997. doi:10.1126/science.276.5321.2045

2. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer s & Dementia. 2012. doi:10.1016/j.jalz.2011.10.007

3. Loh JS, Mak WQ, Tan L, et al. Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduction and Targeted Therapy. 2024. doi:10.1038/s41392-024-01743-1

4. Cristaldi A, Fiore M, Conti GO, et al. Possible association between PM2.5 and neurodegenerative diseases: A systematic review.. Environmental Research. 2021. doi:10.1016/j.envres.2021.112581

5. Hou K, Wu Z, Chen X, et al. Microbiota in health and diseases. Signal Transduction and Targeted Therapy. 2022. doi:10.1038/s41392-022-00974-4

6. Gao C, Jiang J, Tan Y, Chen S. Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduction and Targeted Therapy. 2023. doi:10.1038/s41392-023-01588-0

7. Zhang W, Xiao D, Mao Q, Xia H. Role of neuroinflammation in neurodegeneration development. Signal Transduction and Targeted Therapy. 2023. doi:10.1038/s41392-023-01486-5

8. Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zloković BV. Blood-Brain Barrier: From Physiology to Disease and Back. Physiological Reviews. 2018. doi:10.1152/physrev.00050.2017

9. Ma W, Geng Y, Liu Y, et al. The mechanisms of white matter injury and immune system crosstalk in promoting the progression of Parkinson's disease: a narrative review.. Frontiers in aging neuroscience. 2024. doi:10.3389/fnagi.2024.1345918